HRS-1596
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 26, 2026
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple Doses
(clinicaltrials.gov)
- P1 | N=122 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
1 to 1
Of
1
Go to page
1